Features | Native, n = 6 | Mestizo, n = 10 |
---|---|---|
Age, mean (SD) yrs | 54.7 (16.2) | 49.3 (8.4) |
Sex, men/women | 2/4 | 8/2 |
Ethnicity | Quechua (n = 5), Aymara (n = 1) | Quechua and European |
Ancestors | Natives | Native and European: Spanish (n = 9), Italian (n = 1) |
Family history of psoriasis or psoriatic arthritis | No | Yes (n = 2) |
First clinical visit | October 2008 and December 2011 (Aymara native) | October 2008 |
Disease duration, mean yrs (SD) | 4.3 (2.4) | 3.5 (2.1) |
CASPAR criteria fulfillment | Yes | Yes |
Clinical pattern | Polyarticular (n = 2), oligoarticular (n = 1), axial (n = 1), DIP joint (n = 2) | Polyarticular (n = 4), oligoarticular (n = 2), axial (n = 1), DIP joint (n = 3), (2 patients with combination of dactylitis, enthesitis, and axial disease with oligoarticular or polyarticular disease) |
Psoriasis alone, current or ever (n) | Current (n = 4), ever (n = 0) | Current (n = 7), ever (n = 2) |
Nail involvement | n = 4 | n = 5 |
Radiographic damage | Hands (n = 1), feet (n = 1), sacroiliac joint (n = 2), unknown (n = 2) | Hands (n = 4), feet (n = 2), sacroiliac joint (n = 1), unknown (n = 3) |
High C-reactive protein | n = 2 (both dactylitis), 1 polyarticular disease, 1 oligoarticular disease | n = 2; one oligoarticular disease and dactylitis, 1 polyarticular disease and enthesitis |
Rheumatoid factor | Negative (n = 5), unknown (n = 1) | Negative (n = 9), positive (n = 1) with polyarticular, entheseal, and axial involvement |
Current treatment | ||
Nonsteroidal antiinflammatory drugs | Yes (n = 6) | Yes (n = 10) |
Disease-modifying antirheumatic drugs | Yes: Methotrexate (n = 6), dose range: 15–22.5 mg/week | Yes: Methotrexate (n = 8), dose range: 15–22.5 mg/week. No (n = 2): n = 1 spontaneous remission, n = 1 intolerance to methotrexate |
Biologics | n = 1 | n = 1 |
CASPAR = Classification for Psoriatic Arthritis (criteria); DIP = distal interphalangeal.